| "Isolated" low high-density lipoprotein cholesterol. | |
| | |
MedLine Citation:
|
PMID: 8997473 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To present information on the function, structure, and importance of high-density lipoprotein cholesterol (HDL-C) and to evaluate the current literature regarding the controversy of managing patients with an "isolated" low HDL-C concentration. DATA SOURCE: A MEDLINE search was performed (1966-June 1996) to identify English-language clinical and review articles pertaining to HDL-C. Some articles were identified through the bibliography of selected articles. STUDY SECTION: All articles were considered for possible inclusion in the review. Pertinent information, as judged by the authors, was selected for discussion. DATA EXTRACTION: Important historical lipid studies, recent review articles, and clinical trials involving therapy for HDL-C were evaluated. DATA SYNTHESIS: The structure, function, and measurement of HDL-C and the state of an isolated low HDL-C are discussed for background. Lifestyle modification measures to increase HDL-C, medications to avoid, estrogen replacement, and lipid-altering agents used to raise an isolated low HDL-C are presented. CONCLUSIONS: An isolated low HDL-C concentration poses a risk for coronary heart disease. The management of this state is controversial. The first step in management is in agreement with experts and includes lifestyle modification (e.g., weight reduction, diet, smoking cessation, aerobic exercise). Estrogen replacement therapy and discontinuance of drugs that secondarily lower HDL-C are additional treatment options. The use of lipid-altering agents has been used in some patients. Nicotinic acid appears to be an effective agent for an isolated low HDL-C. A large clinical trial evaluating the effect of treating an isolated low HDL-C for primary and secondary prevention of coronary events is needed. |
| | |
Authors:
|
V M Wilt; J G Gums |
Related Documents
:
|
11300613 - Role of phospholipid transfer protein and prebeta-high density lipoproteins in maintain... 19406243 - Human macrophage cholesterol efflux potential is enhanced by hdl-associated 17beta-estr... 19956623 - Loss of pdzk1 causes coronary artery occlusion and myocardial infarction in paigen diet... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: 31 ISSN: 1060-0280 ISO Abbreviation: Ann Pharmacother Publication Date: 1997 Jan |
Date Detail:
|
Created Date: 1997-03-25 Completed Date: 1997-03-25 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 89-97 Citation Subset: IM |
Affiliation:
|
Department of Pharmacy Practice, University of Florida, Gainesville 32164, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cholesterol, HDL
/
blood* Exercise Humans Life Style Lipoproteins, HDL / deficiency*, genetics, physiology* Niacin / therapeutic use Obesity / blood Smoking / adverse effects |
| Chemical | |
Reg. No./Substance:
|
0/Cholesterol, HDL; 0/Lipoproteins, HDL; 59-67-6/Niacin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Respiratory syncytial virus immune globulin intravenous.
Next Document: Lipoprotein disorders in women: which women are the best candidates for hormone replacement therapy?